Document text
Principal Investigator: Luigi Notarangelo
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2024
Award: $236,110
Funding agency: National Institute of Allergy and Infectious Diseases
SARS-CoV-2 infection displays immense inter-individual clinical variability, ranging from silent infection to lethal disease, to multi-system inflammatory syndrome in children (MIS-C) or in adults (MIS-A) that occur 3-4 weeks after acute infection. The mechanisms underlying such broad phenotypic heterogeneity remain largely unknown. Following the development of COVID-19 pandemic, we have established a collaboration with centers in Italy, Chile, and in the United States that have been inflicted by a severe disease burden. We have obtained biological specimens and de-identified clinical and laboratory data from over 1300 patients that have been hospitalized with acute COVID-19, including both adult and pediatric cases. We have also obtained biological specimens from over 100 children with MIS-C and from pediatric controls. Our lab has played a critical role in the distribution of the biological specimens to a large number of intramural investigators. We have performed studies aimed at better defining the molecular and cellular signatures of immune dysfunction associated with acute COVID-19 and MIS-C and at identifying biomarkers and pre-existing clinical conditions that are predictive of poor outcome. We have sought to characterize immunopathological signatures that distinguish the clinical course of COVID-19 infection in children and in adults. We have also aimed at better defining the inflammatory response associated with MIS-C, identifying possible risk factors associated with this condition, and analyzing the impact of treatment on resolution of the inflammation. We have collected biological samples from patients with various forms of inborn errors of immunity (IEI) and from healthcare workers at various time points before and after administration of COVID-19 vaccines, in the intent to analyze the strength and durability of adaptive immune responses and the incidence and severity of adverse events following vaccine administration. Finally, we have aimed at defining whether some of the risk factors associated with increased risk of serious SARS-CoV-2 infection may also be involved in determining an increased risk of breakthrough infection in individuals who have received the COVID-19 vaccine.
Terms: <0-11 years old><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><21+ years old><Adult><Adult Human><Adverse Experience><Adverse event><Antibody Response><B cell repertoire><Biological><Biological Markers><Blood><Blood Reticuloendothelial System><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 period><COVID-19 predisposition><COVID-19 public health crisis><COVID-19 susceptibility><COVID-19 vaccine><COVID-19 virus><COVID-19 virus infection><COVID-19 vulnerability><COVID-19 years><COVID19 infection><COVID19 virus><Child><Child Youth><Childhood><Children (0-21)><Chile><Clinical><CoV-2><CoV2><Collaborations><Coronavirus disease 2019 predisposition><Coronavirus disease 2019 susceptibility><Coronavirus disease 2019 vulnerability><Data><Development><Disease><Disorder><Gene variant><Goals><Health Care Providers><Health Personnel><Healthcare Providers><Healthcare worker><Heterogeneity><Hospital Admission><Hospitalization><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune System Diseases><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immune response><Immunochemical Immunologic><Immunodeficiency and Immunosuppression Disorders><Immunologic><Immunologic Diseases><Immunological><Immunological Diseases><Immunological Dysfunction><Immunological System Dysfunction><Immunological response><Immunologically><Immunologics><Incidence><Individual><Infection><Inflammation><Inflammatory Response><Investigators><Italy><Laboratories><MIS-C><Molecular><Molecular Fingerprinting><Molecular Profiling><Multiorgan Inflammatory Syndrome in Children><Multisystem Inflammatory Syndrome in Children><Outcome><PBMC><Patients><Peripheral Blood Mononuclear Cell><Phenotype><Play><Predisposed to COVID-19><Predisposed to SARS-CoV-2><Predisposed to Severe acute respiratory syndrome coronavirus 2><Primary Immunodeficiency><Research Personnel><Research Specimen><Researchers><Resolution><Risk><Risk Factors><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 predisposition><SARS-CoV-2 susceptibility><SARS-CoV-2 vaccine><SARS-CoV-2 vulnerability><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 predisposition><Severe acute respiratory syndrome coronavirus 2 susceptibility><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vulnerability><Severe acute respiratory syndrome related corona virus 2><Severities><Severity of illness><Specimen><T-Cells><T-Lymphocyte><Time><United States><Vaccines><Wuhan coronavirus><acute COVID-19><acute SARS-CoV-2 infection><acute infection><acute phase of COVID-19><acute phase of SARS-CoV-2 infection><adaptive immune response><adulthood><allele variant><allelic variant><bio-markers><biologic><biologic marker><biomarker><biomarker identification><breakthrough infection><burden of disease><burden of illness><congenital immune deficiency><congenital immunodeficiency><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><developmental><disease burden><disease severity><genetic immune defect><genetic immune deficiency><genetic immunodeficiency><genetic variant><genomic variant><hCoV19><health care personnel><health care worker><health provider><health workforce><healthcare personnel><host response><identification of biomarkers><identification of new biomarkers><immune system response><immunoresponse><inborn errors in immunity><inborn errors of immunity><inborn immunodeficiency><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inherited immune defect><inherited immune deficiency><inherited immunodeficiency><kids><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><marker identification><medical personnel><molecular profile><molecular signature><multisystem inflammatory syndrome of children><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><pediatric><pediatric inflammatory multisystem syndrome><predisposed to Coronavirus disease 2019><primary immune defect><primary immune deficiency><resolutions><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><social role><susceptible to COVID-19><susceptible to Coronavirus disease 2019><susceptible to SARS-CoV-2><susceptible to Severe acute respiratory syndrome coronavirus 2><thymus derived lymphocyte><treatment provider><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID><vulnerable to COVID-19><vulnerable to Coronavirus disease 2019><vulnerable to SARS-CoV-2><vulnerable to Severe acute respiratory syndrome coronavirus 2><youngster>